ID

34346

Descrizione

GP2013 in Japanese Patients With CD20 Positive Low Tumor Burden Indolent B-cell Non-Hodgkin's Lymphoma; ODM derived from: https://clinicaltrials.gov/show/NCT01933516

collegamento

https://clinicaltrials.gov/show/NCT01933516

Keywords

  1. 16/01/19 16/01/19 -
  2. 26/04/20 26/04/20 -
  3. 01/05/20 01/05/20 -
Titolare del copyright

see on clinicaltrials.gov

Caricato su

16 gennaio 2019

DOI

Per favore, per richiedere un accesso.

Licenza

Creative Commons BY-NC 3.0

Commenti del modello :

Puoi commentare il modello dati qui. Tramite i fumetti nei gruppi di articoli e articoli è possibile aggiungere commenti a quelli in modo specifico.

Commenti del gruppo di articoli per :

Commenti dell'articolo per :

Per scaricare i modelli di dati devi essere registrato. Per favore accesso o registrati GRATIS.

Eligibility Indolent B-cell Non-Hodgkin's Lymphoma NCT01933516

Eligibility Indolent B-cell Non-Hodgkin's Lymphoma NCT01933516

Inclusion Criteria
Descrizione

Inclusion Criteria

Alias
UMLS CUI
C1512693
patient with cd20 positive low tumor burden indolent b-cell non- hodgkin's lymphoma.
Descrizione

ID.1

Tipo di dati

boolean

patient with at least one measurable lesion.
Descrizione

ID.2

Tipo di dati

boolean

patient with ecog performance status 0 or 1.
Descrizione

ID.3

Tipo di dati

boolean

Exclusion Criteria
Descrizione

Exclusion Criteria

Alias
UMLS CUI
C0680251
patient who has received radiotherapy within the last 28 days prior to administration, or are not recovered from previous radiotherapy.
Descrizione

ID.4

Tipo di dati

boolean

patient who has received immunotherapy, chemotherapy, antibodies and experimental treatment within the last 28 days prior to administration, or are not recovered from previous therapy.
Descrizione

ID.5

Tipo di dati

boolean

patient who has mab therapy other than rituximab as prior line of therapy.
Descrizione

ID.6

Tipo di dati

boolean

patient with evidence of any uncontrolled, acute or chronic active infection (viral, bacterial or fungal).
Descrizione

ID.7

Tipo di dati

boolean

patient with any other malignancy within 5 years prior to date of screening, with the exception of adequately treated in situ carcinoma of the cervix uteri, basal or squamous cell carcinoma or nonmelanomatous skin cancer.
Descrizione

ID.8

Tipo di dati

boolean

other protocol-defined inclusion/exclusion criteria may apply.
Descrizione

ID.9

Tipo di dati

boolean

Similar models

Eligibility Indolent B-cell Non-Hodgkin's Lymphoma NCT01933516

Name
genere
Description | Question | Decode (Coded Value)
Tipo di dati
Alias
Item Group
C1512693 (UMLS CUI)
ID.1
Item
patient with cd20 positive low tumor burden indolent b-cell non- hodgkin's lymphoma.
boolean
ID.2
Item
patient with at least one measurable lesion.
boolean
ID.3
Item
patient with ecog performance status 0 or 1.
boolean
Item Group
C0680251 (UMLS CUI)
ID.4
Item
patient who has received radiotherapy within the last 28 days prior to administration, or are not recovered from previous radiotherapy.
boolean
ID.5
Item
patient who has received immunotherapy, chemotherapy, antibodies and experimental treatment within the last 28 days prior to administration, or are not recovered from previous therapy.
boolean
ID.6
Item
patient who has mab therapy other than rituximab as prior line of therapy.
boolean
ID.7
Item
patient with evidence of any uncontrolled, acute or chronic active infection (viral, bacterial or fungal).
boolean
ID.8
Item
patient with any other malignancy within 5 years prior to date of screening, with the exception of adequately treated in situ carcinoma of the cervix uteri, basal or squamous cell carcinoma or nonmelanomatous skin cancer.
boolean
ID.9
Item
other protocol-defined inclusion/exclusion criteria may apply.
boolean

Si prega di utilizzare questo modulo per feedback, domande e suggerimenti per miglioramenti.

I campi contrassegnati da * sono obbligatori.

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial